Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

PRLD | Prelude Therapeutics Inc

Index	RUT	P/E	-	EPS (ttm)	-2.35	Insider Own	54.09%	Shs Outstand	36.50M	Perf Week	-13.25%
Market Cap	150.73M	Forward P/E	-	EPS next Y	-2.09	Insider Trans	6.26%	Shs Float	25.16M	Perf Month	-23.18%
Income	-116.75M	PEG	-	EPS next Q	-0.58	Inst Own	45.94%	Short Float / Ratio	6.84% / 13.91	Perf Quarter	-38.20%
Sales	0.00M	P/S	-	EPS this Y	5.12%	Inst Trans	-2.05%	Short Interest	1.72M	Perf Half Y	-57.30%
Book/sh	4.78	P/B	0.58	EPS next Y	9.72%	ROA	-43.27%	Target Price	8.25	Perf Year	-59.32%
Cash/sh	4.65	P/C	0.59	EPS next 5Y	-	ROE	-46.43%	52W Range	2.66 - 8.66	Perf YTD	-54.47%
Dividend	-	P/FCF	-	EPS past 5Y	-64.12%	ROI	-44.55%	52W High	-68.26%	Beta	0.43
Dividend %	-	Quick Ratio	17.13	Sales past 5Y	0.00%	Gross Margin	-	52W Low	3.38%	ATR	0.25
Employees	122	Current Ratio	17.13	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	25.90	Volatility	7.05% 7.75%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	6.55%	Profit Margin	-	Rel Volume	0.79	Prev Close	2.81
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 03 BMO	Payout	-	Avg Volume	123.78K	Price	2.75
Recom	2.75	SMA20	-20.07%	SMA50	-25.84%	SMA200	-48.26%	Volume	47,863	Change	-2.14%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-22	Downgrade	BofA Securities	Neutral → Underperform	$8 → $6
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19 → $11
Jul-29-22	Initiated	Jefferies	Buy	$9
Mar-15-22	Downgrade	BofA Securities	Buy → Neutral	$50 → $10
Feb-28-22	Downgrade	Barclays	Overweight → Equal Weight	$20 → $12
Oct-08-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-27-21	Upgrade	BofA Securities	Neutral → Buy	$60
Apr-26-21	Initiated	H.C. Wainwright	Buy	$62
Mar-09-21	Initiated	Barclays	Overweight	$80
Nov-20-20	Downgrade	BofA Securities	Buy → Neutral	$40 → $60
Oct-20-20	Initiated	Morgan Stanley	Equal-Weight	$34
Oct-20-20	Initiated	Goldman	Neutral	$37
Oct-20-20	Initiated	BofA Securities	Buy	$40

Show Previous Ratings

Aug-29-23 08:30AM	Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-03-23 08:00AM	Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-10-23 08:13AM	We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-02-23 11:36AM	Insider Buying Alert: These 10 Stocks are Seeing Significant Insider Activity (Insider Monkey)
08:30AM	Loading…
May-31-23 08:30AM	Prelude Therapeutics To Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-28-23 08:11AM	Krishna Vaddi Buys Handful Of Shares In Prelude Therapeutics \ (Simply Wall St.)
May-18-23 07:00AM	Prelude Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -11.43%
May-17-23 04:08PM	Prelude Therapeutics Announces Launch of Proposed Public Offering (GlobeNewswire)
May-08-23 08:30AM	Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update (GlobeNewswire)
Apr-27-23 08:30AM	Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May (GlobeNewswire)
Apr-11-23 08:30AM	Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference (GlobeNewswire) +9.01%
Apr-07-23 09:34AM	Prelude Therapeutics Incorporated (NASDAQ:PRLD) most popular amongst private equity firms who own 33% of the shares, institutions hold 24% (Simply Wall St.)
Mar-18-23 06:48PM	The 7 Worst Stocks to Buy Now (InvestorPlace)
Mar-16-23 12:06PM	Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate (Zacks)
08:30AM	Loading…
Mar-15-23 08:30AM	Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +8.49%
08:00AM	Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers (GlobeNewswire)
Mar-01-23 08:30AM	Prelude Therapeutics To Participate in Barclays Global Healthcare Conference (GlobeNewswire)
Feb-09-23 09:05AM	Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire)
Jan-30-23 09:38AM	We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate (Simply Wall St.) -5.45%
Dec-24-22 07:05AM	Krishna Vaddi Is The Founder of Prelude Therapeutics Incorporated (NASDAQ:PRLD) And Just Spent US$98k On Shares (Simply Wall St.)
Nov-25-22 08:06AM	Prelude Therapeutics Incorporated (NASDAQ:PRLD) drops to US$317m and insiders who purchased earlier this year lose another US$17k (Simply Wall St.)
Nov-14-22 08:00AM	Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -8.82%
Oct-18-22 08:00AM	Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader (GlobeNewswire)
Sep-06-22 08:00AM	Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences (GlobeNewswire) -5.48%
Aug-23-22 06:39AM	Prelude Therapeutics (NASDAQ:PRLD) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-10-22 09:25AM	Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season? (Zacks) +22.43%
Aug-09-22 08:00AM	Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Jul-05-22 09:22PM	'I wanted to build it here': Life sciences startup leaders talk about challenges of growing in Philadelphia (American City Business Journals)
Jun-22-22 09:55AM	Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know (Zacks)
06:35AM	Loading…
May-25-22 06:35AM	Prelude Therapeutics Incorporated (NASDAQ:PRLD) drops to US$206m and insiders who purchased earlier this year lose another US$60k (Simply Wall St.)
May-10-22 08:00AM	Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update (GlobeNewswire) +9.50%
Mar-16-22 07:30AM	Prelude Therapeutics Reports Full Year 2021 Financial Results (GlobeNewswire) +8.39%
06:39AM	Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-11-22 08:00AM	Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference (GlobeNewswire)
Mar-09-22 08:05AM	Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting (GlobeNewswire) +7.53%
08:00AM	Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer (GlobeNewswire)
Feb-11-22 07:00AM	Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-04-22 07:00AM	Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire) -13.54%
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-16-21 09:41AM	In spite of Prelude Therapeutics Incorporated's recent pullback, insiders still gained about US$12k after buying earlier this year. (Simply Wall St.)
Dec-15-21 07:15PM	Prelude Therapeutics Inc (PRLD) EVP, Head of Chemistry Andrew Combs Bought $94,880 of Shares (GuruFocus.com) +11.86%
Dec-08-21 08:47AM	Prelude Therapeutics Inc. signs deal to move headquarters to Chestnut Run in Wilmington (American City Business Journals)
Nov-23-21 07:00AM	Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +5.51%
Nov-19-21 11:51AM	Notable Prelude Therapeutics Insider Trades $820K In Company Stock (Benzinga)
Nov-12-21 08:00AM	Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update (GlobeNewswire)
Nov-08-21 09:00AM	Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor (GlobeNewswire)
Oct-18-21 08:24PM	Morgan Stanley: Buy These 2 Stocks Before They Jump 80% (Or More) (TipRanks)
Oct-07-21 03:12PM	Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher (Benzinga) -39.75%
12:55PM	Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today? (Benzinga)
12:28PM	Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide (Benzinga)
11:15AM	Notable Prelude Therapeutics Insider Trades $490K In Company Stock (Benzinga)
10:16AM	Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Beats Views (Benzinga)
09:00AM	Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-25-21 10:06AM	15 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Sep-09-21 07:07PM	Chief Medical Officer Of Prelude Therapeutics Trades $578.63 Thousand In Company Stock (Benzinga)
Sep-02-21 07:00AM	Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences (GlobeNewswire)
Aug-12-21 07:30AM	Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update (GlobeNewswire)
Aug-11-21 06:49AM	We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate (Simply Wall St.) +6.32%
Jul-19-21 07:00AM	Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors (GlobeNewswire) +10.50%
May-13-21 07:15AM	Are Insiders Buying Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock? (Simply Wall St.) -11.63%
May-11-21 07:30AM	Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update (GlobeNewswire)
May-05-21 07:00AM	Prelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference (GlobeNewswire)
Apr-20-21 07:42AM	Prelude Therapeutics (PRLD) Enters Oversold Territory (Zacks) +5.53%
Mar-16-21 08:00AM	Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update (GlobeNewswire)
Mar-03-21 07:00AM	Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences (GlobeNewswire)
Jan-11-21 06:20PM	Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jan-07-21 12:12AM	Prelude Therapeutics Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.59%
Jan-04-21 04:16PM	Prelude Therapeutics Announces Launch of Proposed Public Offering (GlobeNewswire) -5.72%
Dec-25-20 04:01AM	Here's Why We're Not At All Concerned With Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation (Simply Wall St.)
Dec-15-20 11:42PM	Is PRLD A Good Stock To Buy Now? (Insider Monkey)
Nov-10-20 07:30AM	Prelude Therapeutics Announces Third Quarter 2020 Financial Results (GlobeNewswire)
Oct-02-20 08:00PM	Metacrine, Prelude Therapeutics See Activist Action (Barrons.com)
Oct-01-20 11:57AM	Biotech Pulmonx Shares Climb in Trading Debut (Barrons.com) +11.18%
Sep-30-20 07:00AM	Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies (GlobeNewswire)
Sep-29-20 04:05PM	Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Sep-25-20 02:31PM	PMV Pharma Soars 115% as Biotech IPOs Take Off (Barrons.com)
08:47AM	Four Biotech Companies Are Going Public Today. What to Know About Each. (Barrons.com)
Sep-24-20 08:50PM	Prelude Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)
10:52AM	Biotech Taysha Gene Therapies Climbs in Trading Debut (Barrons.com)

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vaddi Krishna	CEO	May 25	Buy	5.31	900	4,779	1,067,275	May 26 04:20 PM
Lim Bryant David	Chief Legal Officer, Corp Sec.	May 24	Buy	5.39	2,400	12,936	2,400	May 25 04:07 PM
Vaddi Krishna	CEO	May 24	Buy	5.01	1,000	5,011	1,066,375	May 26 04:20 PM
Vaddi Krishna	CEO	May 23	Buy	5.63	11,856	66,749	1,065,375	May 25 04:03 PM
Chardonnet Laurent	Chief Financial Officer	May 23	Buy	5.50	5,000	27,500	42,165	May 25 04:05 PM
ORBIMED ADVISORS LLC	Director	May 22	Buy	5.75	869,565	4,999,999	10,119,756	May 24 05:09 PM
Bonita David P	Director	May 22	Buy	5.75	869,565	4,999,999	10,119,756	May 24 05:07 PM
Huang Jane	President, CMO	Apr 06	Sale	6.12	13,280	81,274	24,220	Apr 06 06:19 PM
Vaddi Krishna	CEO	Dec 20	Buy	5.13	19,188	98,446	120,665	Dec 21 04:08 PM
Chardonnet Laurent	Chief Financial Officer	Dec 08	Buy	4.76	10,000	47,600	35,873	Dec 12 09:13 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRLD | Prelude Therapeutics Inc

Upgrade your FINVIZ experience